Company / Cash & Equivalents
Elanco Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$545.0M
FY2025
5-year range
$345.0M / $638.0M
FY2021-FY2025
Trend
+16.5%
vs FY2024
Sector context
#39 of 207
Health Care
What the data says
Elanco's cash & equivalents of $545M is higher than 81% of companies in the Health Care sector (FY2025). Cash & Equivalents has increased for 3 consecutive years, from $345M in FY2022 to $545M in FY2025.
Based on SEC 10-K filings.
$545M in FY2025 with a 5-year CAGR of +1.9%. Top quartile in the Health Care sector.
Improved from $352M to $545M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +16.5%
- 5-Year CAGR
- +1.9%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 207This company $545.0M Sector average $669.5M
▼
-18.6% below sector average
Key checks
Key Insights
- Elanco's cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +1.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 16.5% year-over-year.
- Ranks #39 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $545.0M | +16.5% |
| FY2024 | $468.0M | +33.0% |
| FY2023 | $352.0M | +2.0% |
| FY2022 | $345.0M | -45.9% |
| FY2021 | $638.0M | +28.9% |
| FY2020 | $495.0M | +48.2% |
| FY2019 | $334.0M | -29.7% |
| FY2018 | $474.8M | +46.8% |
| FY2017 | $323.4M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026